Event-Driven Stocks

LIPOSCIENCE INC

Healthcare · In Vitro & In Vivo Diagnostic Substances · DE · SEC filings ↗ · Compare ⊕

Signs1 good3 warningdetails ↓

Financials

SEC XBRL · annual
 FY13FY12
Revenue
Operating income−$2.3M$1.5M
Net income−$2.8M$1.3M
Total assets$72.0M$47.7M
Total liabilities$24.2M$29.9M
Equity$47.8M−$39.6M
EPS (diluted)$-0.19$0.13
Shares out.15.2M1.9M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2013
Operating margin
Net margin
Return on equity
−6.0%
Return on assets
−4.0%
Return on capital (ROCE)
−4.6%
Liabilities / assets
33.7%
Debt / equity
0.51×
Book value / share
$3.14
Revenue growth (YoY)
Net income growth (YoY)
−324.4%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2013
Altman Z″ (distress)
2.30grey zone
Accruals / assets
10.2%high accruals
Piotroski F-Score
1/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
22
/ 100
Profitability 0Growth 0Catalyst 33Earnings quality 0Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

3 warning1 good
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Altman Z″ in the grey zone
  • Conservative leverage (liabilities < 50% of assets)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
1 acquisitions11 disposalsnet 754,499 shares · last 12
InsiderDateTypeSharesPrice
Zakrzewski Joseph SDirectorNov 20, 2014D25,372$5.25
Young Roderick ADirectorNov 20, 2014D10,077$5.25
Twiddy KathrynOfficer — VP, General Counsel, SecretaryNov 20, 2014D27,500$5.25
Otvos James D.Officer — EVP, Chief Scientific OfficerNov 20, 2014D504,771$5.25
Mcdonald E. DuffyOfficer — Vice President, HRNov 20, 2014D23,765$5.25
Martindale Lucy G.Officer — EVP and CFONov 20, 2014D107,881$5.25
Levangie Daniel JDirectorNov 20, 2014D10,077$5.25
Hurley James RDirectorNov 20, 2014D12,670$5.25
Hilldale Philip DOfficer — Vice President of SalesNov 20, 2014Grant60,000$0.00
Greczyn Robert J JrDirectorNov 20, 2014D18,046$5.25
Doran Howard JrOfficer — President and CEONov 20, 2014D52,884$5.25
Cromwell William COfficer — Chief Medical OfficerNov 20, 2014D21,456$5.25

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.